315 results about "Gout" patented technology

The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1-5. The uric acid reducing effect is verified by adopting an in-vitro XOD inhibition experiment and a cell experiment; furthermore, the uric acid reducing and gout resisting activity of the compound is verified through a hyperuricemia animal model, and a theoretical basis is provided for high-valued utilization of the belly-swelling hippocampus and development of uric acid reducing and gout resisting products.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

The invention provides a gout diagnosis and recurrence risk prediction method and system based on Raman spectrum and multi-modal machine learning, and the method comprises the steps: generating a Raman spectrum sample data set, and carrying out the preprocessing; performing data dimension reduction and feature extraction on the preprocessed Raman spectrum sample data set to obtain key feature vectors; performing feature screening and enhancement on the key feature vectors before modeling; modeling the data before and after dimension reduction by using a machine learning algorithm to obtain a plurality of machine learning models; and training the multiple machine learning models by using a training set, verifying the models by using a ten-fold cross validation method, selecting the machine learning model with the best discrimination effect as a prediction model, and performing risk prediction of medical history development and gout recurrence. The Raman spectrum and the advanced artificial intelligence technology are integrated, a new prospect is provided for identifying unique metabolic characteristics related to the diseases, the clinical management level of gout is improved, and intervention is earlier and more accurate.

The invention provides application of indole-3-lactic acid in preparation of uric acid reducing products, and relates to the technical field of medicines. The indole-3-lactic acid is found to have a good blood uric acid reducing effect for the first time, a new uric acid reducing medicine component is provided for health-care food, hyperuricemia and related diseases thereof, and the indole-3-lactic acid is small in renal function damage and is a safe and efficient uric acid reducing functional component. The gout treatment mechanism of the indole-3-lactic acid is mainly realized by relieving the inflammatory response of the organism and improving uric acid excretion, and the indole-3-lactic acid has dual effects, is different from the mechanism of the existing medicine, and has unique innovation.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention relates to an application of a sugarcane polyphenol extract in preparation of a medicine for preventing and / or treating hyperuricemia. The invention also discloses application of the sugarcane polyphenol extract in medicines or health care products for gout caused by hyperuricemia, chronic gout, liver injury and kidney injury. The technical problem to be solved is how to provide the sugarcane polyphenol extract, the sugarcane polyphenol extract contains at least 32 polyphenol monomers, the uric acid reducing effect is improved through the synergistic effect among the polyphenol monomers, and the sugarcane polyphenol extract can be used for preparing drugs or health care products for preventing and / or treating hyperuricemia.

The invention relates to the technical field of pharmaceutical preparations, and provides an oral solid preparation for treating gout and a preparation method thereof. The preparation method comprises the following steps: sieving a filling agent, a disintegrating agent, an adhesive and dotenorad to obtain a sieved material; and mixing the sieved material and a lubricant, and tabletting to obtain the oral solid preparation for treating gout, the filling agent is lactose, mannitol and microcrystalline cellulose. By optimizing the prescription and the preparation process, the dissolution rate and bioavailability of the medicine are improved, so that the curative effect is improved; by selecting proper auxiliary materials and preparation types, the stimulation to gastrointestinal tracts is reduced, and the tolerance of patients is improved; the oral solid preparation is convenient to take, accurate in dosage, high in patient compliance and beneficial to long-term treatment; moreover, the preparation method provided by the invention is simple to operate, easy for industrial production and relatively low in cost.

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.

A food medicine for reducing blood uric acid and treating gout is characterized in that celery seeds, celery, mulberry fruits, mulberry leaves, sea buckthorn fruit powder, dandelions, rhizoma polygonati, poria cocos and beach kidney grass serve as a basic formula; the auxiliary materials comprise one, several or all of a plurality of formula combinations of ramulus mori, lycium ruthenicum, radix puerariae, Chinese yam, clerodendranthus spicatus, lysimachia christinae hance, acanthopanax, anserine, astragalus membranaceus, purslane, herba cepbalanoplosis segeti, galangal, hovenia dulcis thunb, astragalus membranaceus, luteolin, uric acid-reducing edible probiotics and the like, and are used for treating hyperuricemia and gout.

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.

The present application relates to an NEK7 inhibitor, a pharmaceutical composition and a use thereof. The compound has a structural formula of formula (I). The compound of the present disclosure has good NEK7 inhibitory activity, and can be used for treating or preventing inflammatory pathological disorders (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, ulcerative colitis, Crohn's disease, cancer, osteoarthritis, gout, etc.) regulated by the NLRP3 inflammasome.

The invention provides a preparation method and application of borneol water with high natural borneol content, and belongs to the technical field of medicines, daily chemicals and aromatherapy. The invention provides a preparation method of borneol water with high natural borneol content, and the borneol water is prepared by directly adopting fresh crushed cinnamomum camphora leaves as a borneol donor based on a two-stage vacuum steam distillation-cyclodextrin reversible carrying coupling process. According to the method, through a'two-stage vacuum steam distillation-cyclodextrin reversible carrying 'coupling process, the content of borneol in a water phase reaches 0.60 + / -0.05 g / 100mL, the chemical purity is greater than or equal to 96%, and meanwhile, long-term clarification and stability are ensured. The obtained borneol water can be effectively used for treating infant eczema, chronic kidney disease related pruritus and relieving / inhibiting pain in the acute outbreak period of gout.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus reuteri JNL0037 and application thereof. The invention provides lactobacillus reuteri JNL0037, which is preserved in the China General Microbiological Culture Collection Center on December 27, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO: 33218. The lactobacillus reuteri JNL0037 can be used for preparing the lactobacillus reuteri JNL0037. The Lactobacillus reuteri JNL0037 provided by the invention has nucleoside degradation, anti-inflammatory and bacteriostatic capabilities, can be used for preparing drugs for treating hyperuricemia, gout and uric acid nephropathy, has extremely high development value and practical value, and provides a new idea for development and application of related products.

The invention discloses a quality detection method of a gout clearing mixture for treating hyperuricemia, which adopts a separation analysis technology of ultra-high performance liquid chromatography to detect eight chemical components in the gout clearing mixture. Comprising the following components: 3-O-feruloylquinic acid, 5-O-caffeoylshikimic acid, paeoniflorin, polydatin, neoastilbin, astilbin, berberine hydrochloride and emodin-8-beta-D-glucopyranoside. According to the method, eight chemical components of six active components in the gout clearing mixture are quantitatively analyzed at the same time, and the method has the advantages of being easy and convenient to operate, good in stability and easy to popularize. The invention can provide a comprehensive and reliable quality control basis for the gout clearing mixture, and has important significance for ensuring the clinical curative effect of the gout clearing mixture.

The present disclosure relates to uricase variant polypeptides and their multimers, as well as uricase conjugates comprising (i) a first domain comprising one of the uricase variant polypeptides conjugated to (ii) a second domain comprising a random coil polypeptide domain. Methods of using the uricase variant polypeptides and uricase conjugates to treat gout, tumor lysis syndrome, and other diseases associated with elevated uric acid levels in body fluids, including blood, are provided. Methods of recombinantly producing the uricase variant polypeptides and uricase conjugates disclosed herein are also provided.

The invention discloses a medicinal and edible traditional Chinese medicine solid beverage for preventing and treating gout and reducing hypertension, hyperglycemia and hyperlipidemia, which comprises 25 medicinal and edible raw materials such as 20-30 parts of chrysanthemum, 15-20 parts of hawthorn and the like, preferably 25 g of chrysanthemum, 35 g of kudzuvine root and the like. The preparation method comprises the following steps: screening, washing, drying, processing by an ancient method, crushing, sieving by a 120-300-mesh sieve, mixing to prepare a material A, and processing into a bag or granular beverage. The beverage is free of toxic and side effects, free of saccharides and chemical additives, and capable of preventing and treating gout and'four highs', promoting excretion and metabolism of uric acid and enhancing immunity; the traditional Chinese medicine composition can soften heart and cerebral vessels, reduce carotid plaques, prevent thrombus and prevent cardiovascular and cerebrovascular diseases, has health-care and health-preserving effects, and is remarkable in curative effect through experimental verification.

The present invention provides a pharmaceutical composition for treating gout. The composition is composed of multiple Chinese medicinal materials such as goldenseal root and white atractylodes macrocephala. The composition is used to treat gout attacks by clearing and tonifying the spleen and stomach, promoting qi circulation, and activating meridians and strengthening tendons. The composition has significant effects and is suitable for promotion and application.

The invention belongs to the technical field of traditional Chinese medicine detection, and particularly relates to a method for determining the content of multiple components in gout pills, which adopts high performance liquid chromatography to simultaneously determine the content of effective components such as aesculin, syringin, corilagin, ellagic acid and chebulilic acid in the gout pills, and adopts ultraviolet spectrophotometry to determine the content of total alkaloids in the gout pills. The method can effectively shorten the analysis time of main effective components in the gout pills, has a good linear range, is high in accuracy, precision and repeatability, is stable and feasible, and can be applied to content determination and quality standard of the gout pills.

The present application relates to the preparation and application field of biological peptide, and more particularly to a hippocampus abdominalis peptide and its application in preparation of products for reducing uric acid and resisting gout. The amino acid sequence is shown as SEQ ID NO. 1, and the present application confirms the uric acid reducing effect through in vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on this basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a high uric acid animal model. This achievement provides a solid theoretical support for high-value development and utilization of hippocampus abdominalis, and research and development of products for reducing uric acid and resisting gout.

The utility model relates to external hot compress equipment technical field, specifically is a kind of gout conditioning machine external hot compress equipment, including concave support frame, cotton pad A and slide rail, the concave support frame top is equipped with hot compress mouth, and the concave support frame top is equipped with seat plate;The concave support frame one side top is equipped with pull-out opening, and the slide rail between is equipped with support frame through pull-out opening, and the inner wall of support frame is evenly equipped with thermostatic electric heating tube by bolt from left to right, and the concave support frame inboard is equipped with support frame corresponding pull-out opening bottom;By the slide rail cooperation support frame sliding or return corresponding hot compress mouth bottom, by the thermostatic electric heating tube of support frame inboard constant-temperature heating, to facilitate hot compress operation, by air hole and cotton pad A be cotton fibre and have good air permeability, by seat plate in hot compress mouth top to facilitate personnel sitting posture hot compress.

This invention discloses a benzofuran compound and its application in lowering uric acid activity. Compounds 1-3 were isolated from the fermentation products of the endophytic fungus *Septoriella phragmitis*, with compound 1 being a novel compound. The fermentation products were purified using mixed solvent extraction, normal silica gel column chromatography, and high-performance liquid chromatography to obtain compounds 1-3. The inhibitory activity of compounds 1-3 on xanthine oxidase, a target related to gout symptoms, was tested. Experimental results showed that the novel compound 1 exhibited good inhibitory activity against xanthine oxidase. Molecular docking experiments also demonstrated that compound 1 had a good binding energy to the target protein. Therefore, compound 1 can be used to prepare a natural lead compound for delaying or treating diseases caused by xanthine oxidase, providing a potential therapeutic agent for hyperuricemia and gout.

The invention discloses phthalide compounds as well as a preparation method and application thereof. The phthalide compounds comprise a compound 1 and a compound 2 as well as a preparation method and application thereof. The two compounds are separated and purified from the ethyl acetate extract of the traditional Chinese medicine ligusticum wallichii for the first time. An in-vitro biological activity test shows that the two compounds have obvious inhibitory activity on xanthine oxidase, which indicates that the two compounds can be used as novel potential candidate drugs for treating hyperuricemia and gout. The embodiment of the invention provides a preparation method, structural identification and pharmacological action of the two phthalide compounds, and provides a new strategy for treatment of hyperuricemia and gout diseases.

The invention provides pain-relieving and stasis-dissipating powder for treating soft tissue and gout, and relates to the technical field of traditional Chinese medicines. The pain-relieving and stasis-dissipating powder for treating soft tissue and gout is prepared from cortex phellodendri, fructus gardeniae, frankincense, myrrh, radix et rhizoma rhei, radix angelicae sinensis, radix angelicae and borneol. The pain-relieving and blood stasis-dissipating powder has the effects of promoting blood circulation to remove blood stasis, relieving swelling and pain, clearing heat, eliminating dampness, removing blood stasis and promoting tissue regeneration, and has a remarkable curative effect on early fracture, soft tissue injury, gout, synovitis and the like.

The present disclosure describes topical ketorolac compositions that comprise a eutectic solvent, such as choline chloride and propylene glycol, and methods and uses thereof. The compositions of the present disclosure are capable of delivering an effective amount of ketorolac through the skin and are believed to be useful in treating inflammation and / or pain, such as gout.

The invention relates to application of puerarin peptide in preparation of anti-inflammatory and / or uric acid-reducing drugs, and relates to the technical field of drugs. The preparation method of the kudzuvine root peptide comprises the following steps: taking kudzuvine root, extracting to obtain soluble protein, dialyzing to obtain dialyzed protein, performing enzymolysis to obtain crude polypeptide, and purifying to obtain the kudzuvine root peptide. The puerarin peptide is high in purity and strong in activity, can remarkably inhibit inflammatory reaction, reduce the level of inflammatory factors and effectively relieve inflammatory symptoms, and provides a new efficient natural medicine choice for treatment of inflammatory diseases; meanwhile, the pharmaceutical composition can effectively reduce the serum uric acid level of a hyperuricemia animal model, regulate uric acid transport related gene expression to promote uric acid excretion and improve renal functions and histopathologic injury, shows a good uric acid reducing effect, is high in safety and free of obvious toxic and side effects, and is expected to become an innovative medicine for treating hyperuricemia and gout.